Reprint
Botulinum Toxin for Urinary Tract Disease
After a Decade from Approval
Edited by
January 2026
138 pages
- ISBN 978-3-7258-6338-9 (Hardback)
- ISBN 978-3-7258-6339-6 (PDF)
Print copies available soon
This is a Reprint of the Special Issue Botulinum Toxin for Urinary Tract Disease: After a Decade from Approval that was published in
Medicine & Pharmacology
Summary
Botulinum toxin was approved by the Food and Drug Administration in 2011 for neurogenic bladder and in 2013 for idiopathic overactive bladder (OAB). In this Special Issue, we address the question of where we stand with this therapy a decade later. Has it prevailed and been proven useful? Which techniques have become established, and how were they optimized? Are more practical ways of distribution on the way? What acceptance problems or obstacles to long-term use might exist among patients or doctors? What are the risks? Has the therapy gained a foothold in the outpatient sector?